Claro Scientific, LLC is a biotechnology startup founded in 2006, based in the United States. The company has developed the patented SpectraWave system, which addresses the critical need for timely, accurate, and actionable healthcare information. This system also has applications in research, protein and cellular analysis, environmental analysis, and biodefense.
Claro's breakthrough lies in the disruptive nature of the SpectraWave system, which redefines how optics can be applied to medical diagnostic and patient monitoring applications. By integrating several discrete optical analysis methods, the system delivers a powerful combination of unique and confirmatory information, achieving the levels of sensitivity, specificity, and limits of detection required for today’s hospital laboratory requirements.
The last investment in Claro Scientific was an $800.00K Venture Round investment on 21 August 2017. Currently, the company does not disclose information about specific investors.
The SpectraWave system is characterized by its portability and reagentless nature, making it adaptable for use in various settings including laboratories, clinics, and field applications. Users can benefit from improved quality, better outcomes, and cost savings across different areas such as patient care, product development, and process optimization.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $800.00K | - | 21 Aug 2017 | |
| Seed Round | $125.00K | - | 01 Apr 2010 |
No recent news or press coverage available for Claro Scientific, LLC.
We care about your data, and we'd love to use cookies make your experience better.